Evogene Ltd (EVGN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.53 is considered Overvalued compared with the five-year average of -1.77. The fair price of Evogene Ltd (EVGN) is between 0.21 to 0.64 according to relative valuation method. Compared to the current price of 0.85 USD , Evogene Ltd By Overvalued By 33.3%.

Relative Value

Fair Zone

0.21-0.64

Current Price：0.85

33.3%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Evogene Ltd (EVGN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Evogene Ltd (EVGN) has a current Price-to-Book (P/B) ratio of 8.62. Compared to its 3-year average P/B ratio of 1.59, the current P/B ratio is approximately 443.30% higher. Relative to its 5-year average P/B ratio of 1.53, the current P/B ratio is about 463.91% higher. Evogene Ltd (EVGN) has a Forward Free Cash Flow (FCF) yield of approximately -173.19%. Compared to its 3-year average FCF yield of -126.41%, the current FCF yield is approximately 37.01% lower. Relative to its 5-year average FCF yield of -95.64%, the current FCF yield is about 81.08% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for EVGN competitors is 0.71, providing a benchmark for relative valuation. Evogene Ltd Corp (EVGN.O) exhibits a P/S ratio of 3.53, which is 400% above the industry average. Given its robust revenue growth of -82.07%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of EVGN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of EVGN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is EVGN currently overvalued or undervalued?

What is Evogene Ltd (EVGN) fair value?

EVGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Evogene Ltd (EVGN) is between 0.21 to 0.64 according to relative valuation method.

How does EVGN's valuation metrics compare to the industry average?

The average P/S ratio for EVGN's competitors is 0.71, providing a benchmark for relative valuation. Evogene Ltd Corp (EVGN) exhibits a P/S ratio of 3.53, which is 400.00% above the industry average. Given its robust revenue growth of -82.07%, this premium appears unsustainable.

What is the current P/B ratio for Evogene Ltd (EVGN) as of Mar 04 2026?

As of Mar 04 2026, Evogene Ltd (EVGN) has a P/B ratio of 8.62. This indicates that the market values EVGN at 8.62 times its book value.

What is the current FCF Yield for Evogene Ltd (EVGN) as of Mar 04 2026?

As of Mar 04 2026, Evogene Ltd (EVGN) has a FCF Yield of -173.19%. This means that for every dollar of Evogene Ltd's market capitalization, the company generates -173.19 cents in free cash flow.

What is the current Forward P/E ratio for Evogene Ltd (EVGN) as of Mar 04 2026?

As of Mar 04 2026, Evogene Ltd (EVGN) has a Forward P/E ratio of -0.97. This means the market is willing to pay $-0.97 for every dollar of Evogene Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Evogene Ltd (EVGN) as of Mar 04 2026?

As of Mar 04 2026, Evogene Ltd (EVGN) has a Forward P/S ratio of 3.53. This means the market is valuing EVGN at $3.53 for every dollar of expected revenue over the next 12 months.

EVGN Valuation